Preferred Label : lixisenatide;

MeSH note : a synthetic glucagon-like peptide 1 (GLP-1) receptor agonist; binds GLP-1 receptor; has antidiabetic effects in mice; amino acid sequence is H-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSK KKKKK-NH2 (ZP10A);

CISMeF synonym : AQVE-10010; AVE 0010; zealand pharma brand of lixisenatide; ZP10A peptide;

MeSH synonym : DES-38-proline-exendine-4 (Heloderma suspectum)-(1-39)-peptidylpenta-l-lysyl-l-lysinamide;

MeSH hyponym : ZP-10; AVE-010; AVE0010; AVE-0010;

Is substance : O;

UNII : 74O62BB01U;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3283446/fr/lyxumia-10-20-microgrammes-lixisenatide
2021
false
false
false
France
evaluation of the transparency committee
lyxumia
lixisenatide
peptides
treatment outcome
insurance, health, reimbursement
hypoglycemic agents
diabetes mellitus, type 2
lixisenatide
injections, subcutaneous
Product containing only lixisenatide in parenteral dose form (medicinal product form)
Glucagon-Like Peptide-1 Receptor
lixisenatide
peptides

---
https://www.has-sante.fr/jcms/p_3282776/fr/suliqua-insuline-glargine-/-lixisenatide
2021
false
false
false
France
evaluation of the transparency committee
insulin
Lixisenatide
insulin
lixisenatide

---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/soliqua-5434.html
2020
false
false
false
Canada
French
insulin glargine and lixisenatide
drug evaluation
Insulin Glargine
drug combinations
diabetes mellitus, type 2
lixisenatide
peptides

---
https://www.ema.europa.eu/medicines/human/EPAR/Suliqua
2017
false
United Kingdom
English
French
Glucagon-Like Peptide-1 Receptor
drug combinations
metformin
Insulin Glargine
Insulin Glargine
Pre-filled Pen Syringe
insulin glargine and lixisenatide
europe
drug approval
treatment outcome
adult
diabetes mellitus, type 2
drug therapy, combination
hypoglycemic agents
hypoglycemic agents
injections, subcutaneous
drug interactions
pregnancy
breast feeding
randomized controlled trials as topic
Glycated Hemoglobin
blood glucose
body weight
drug evaluation, preclinical
summary of product characteristics
package leaflet
drug evaluation
syndication feed
lixisenatide
lixisenatide
peptides
peptides

---
Summary Basis of Decision (SBD) for Adlyxine
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00363
2017
false
Canada
English
French
Glucagon-Like Peptide-1 Receptor
lixisenatide
canada
drug information
drug approval
treatment outcome
adult
diabetes mellitus, type 2
drug therapy, combination
hypoglycemic agents
injections, subcutaneous
lixisenatide
lixisenatide
peptides
peptides

---
http://www.has-sante.fr/portail/jcms/c_2656385/fr/lyxumia
2016
false
France
French
Glucagon-Like Peptide-1 Receptor
insurance, health, reimbursement
evaluation of the transparency committee
lixisenatide
treatment outcome
adult
diabetes mellitus, type 2
drug therapy, combination
hypoglycemic agents
hypoglycemic agents
injections, subcutaneous
Glycated Hemoglobin
blood glucose
lixisenatide
lixisenatide
peptides
peptides

---
https://www.ema.europa.eu/medicines/human/EPAR/Lyxumia
2013
false
United Kingdom
French
Glucagon-Like Peptide-1 Receptor
lixisenatide
europe
drug approval
treatment outcome
adult
diabetes mellitus, type 2
drug therapy, combination
hypoglycemic agents
hypoglycemic agents
injections, subcutaneous
drug interactions
pregnancy
breast feeding
randomized controlled trials as topic
Glycated Hemoglobin
blood glucose
body weight
drug evaluation, preclinical
summary of product characteristics
package leaflet
drug evaluation
syndication feed
lixisenatide
lixisenatide
peptides
peptides

---
Nous contacter.
18/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.